MAP1LC3A and liver cancer: Furthermore, we confirmed the reproducibility of the excellent diagnostic efficacies of TIPRL, LC3 and CD133 levels in HCCs at the different IHC cohort, thus providing reliability of TIPRL, LC3 and CD133 as novel biomarkers for HCCs and early liver cancers.